Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $1.00 → $1.50 | Neutral → Buy | B. Riley Securities |
| 7/30/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 11/3/2021 | $27.00 | Buy | B. Riley Securities |
| 11/3/2021 | $22.00 | Outperform | Oppenheimer |
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine daily for up to one year. The program was made possible through a generous donation from the family of a participant in the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB). "We are grateful to the family who made it possible to provide expanded access to zervimesine for people who were
- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting -- Actively Evaluating Strategy Across DLB and Alzheimer's Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program for zervimesine in mild-to-moderate Alzheimer's disease during the annual Clinical Trials on Alzheimer's Disease (CTAD) conference. Cognition discussed the program design with the U.S. Food and Drug Administration (FDA) during an end-of-Phase 2 meeting. The CTAD poster will be available on the Pu
PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi will participate in an "unplugged" fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel. Details of Cognition's fireside discussion are as follows: Event: 37th Annual Piper Sandler Healthcare Conference Date/Time: Wednesday, December 3rd at 4:30p.m. Eastern Time Webcast: https://event.webcasts.com/starthere.jsp?ei=1742473&tp_key=11
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)
B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously
Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral
B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00
10-Q - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)
PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,
PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c
PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi will participate in an "unplugged" fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel. Details of Cognition's fireside discussion are as follows: Event: 37th Annual Piper Sandler Healthcare Conference Date/Time: Wednesday, December 3rd at 4:30p.m. Eastern Time Webcast: https://event.webcasts.com/starthere.jsp?ei=1742473&tp_key=11
PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled Phase 2 ‘START' Study. A number of additional patients are in the final stages of screening and will be randomized if they meet all eligibility requirements. START will assess the safety and activity of zervimesine (CT1812) in participants with mild cognitive impairment (MCI) or early Alzheimer's disease. Topline results are expected after all participants have completed 18 mo
- Discussed plans to support a pivotal Alzheimer's disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START' study of zervimesine in early Alzheimer's disease - PURCHASE, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "The second quarter of 2025 has been very productive, with milestones from
SC 13G/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13G - COGNITION THERAPEUTICS INC (0001455365) (Subject)
SC 13D/A - COGNITION THERAPEUTICS INC (0001455365) (Subject)